Latest News and Press Releases

Hinzufügung von zwei umsatzgenerierenden, von der FDA zugelassenen Impfstoffen, die gegen Cholera und Typhus schützen, beide mit dualem MarktpotenzialErweiterung der Entwicklungspipeline durch einen...

Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...

Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...

Q2 2018 total revenues of $220 million, net income of $50 millionReaffirms full year 2018 financial forecast and operational goals GAITHERSBURG, Md., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Emergent...

ZIKV-IG granted Fast Track designation by the U.S. Food and Drug Administration GAITHERSBURG, Md., July 31, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the...

GAITHERSBURG, Md., July 18, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 2, 2018 at 5:00 pm (Eastern Time) to discuss the financial...

GAITHERSBURG, Md., June 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate overview and...

Multi-year investment will support growth of contract development and manufacturing capabilities GAITHERSBURG, Md., June 07, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today...

日 オスロ (ノルウェー)、ボルティモアおよびメリーランド州ゲイサーズバーグ発, May 28, 2018 (GLOBE NEWSWIRE) -- CEPI (伝染病蔓延対策の革新のための連合、Coalition for Epidemic Preparedness Innovations) は本日、プロフェクタス･バイオサイエンス (Profectus BioSciences, Inc.)...

OSLO, Norway and BALTIMORE and GAITHERSBURG, Md., May 27, 2018 (GLOBE NEWSWIRE) -- CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus...